Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer

Published:2024-02-22 Issue:5 Volume:67 Page:3419-3436
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Li Chenfan¹,Han Xiaoli¹,Yan Qiuxia²³,Ji Yang¹,Zhang Rongyu¹,Yuan Dazhong¹,Yang Fulian¹,Wang Jianlong³,Wu Meng⁴,Zhou Jinming¹^ORCID

Affiliation:

1. Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Department of Chemistry, Zhejiang Normal University, 688 Yingbin Road, Jinhua 321004, P. R. China

2. Department of Urology, Huizhou First People’s Hospital, Huizhou, Guangdong 516003, P. R. China

3. Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, P. R. China

4. Center for Drug Research and Evaluation, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, P. R. China

Funder

National Natural Science Foundation of China

National High Level Hospital Clinical Research Funding

Jinhua Science and Technology Program Projects (Key)

China Health and Longevity Innovation Competition Funding

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c01668

Reference39 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Targeting the Androgen Signaling Axis in Prostate Cancer

3. Validity and Future of Primary Androgen Deprivation Therapy in Prostate Cancer. Integration in the Era of New Agents Targeting the Androgen Receptor

4. Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment

5. Second generation androgen receptor antagonists and challenges in prostate cancer treatment